Redx Pharma
Alderley Edge, United Kingdom

Redx Pharma specialises in the discovery and development of small molecule therapeutics, with an emphasis on oncology and fibrotic disease. It aims to initially progress them through proof-of-concept studies, before evaluating options for further development and value creation. Existing earlier-stage collaboration partners include AstraZeneca and Jazz Pharmaceuticals.

Investment Perspective

Redx Pharma has a unique and differentiated ROCK inhibitor portfolio, targeting diverse and underserved fibrosis indications. The Phase IIa trial of its lead asset, selective ROCK2 inhibitor zelasudil (RXC007) in idiopathic pulmonary fibrosis (IPF), is due to read out top-line data in H124 and will inform subsequent clinical development plans. This potentially includes expansion into broader interstitial lung diseases (ILDs) and cancer-associated fibrosis. Its second ROCK asset, GI-targeted pan-ROCK inhibitor RXC008 for fibrostenotic Crohn’s disease has now started a Phase I study, with initial safety data in healthy volunteers expected by end-2024. Other key data points in 2024 include Phase II checkpoint inhibitor combination data for porcupine inhibitor RXC004 in Wnt-ligand dependent tumours, expected H124, which will be a prelude to partnership discussions. Continued execution on business development opportunities within the pipeline has led to a third deal with Jazz Pharmaceuticals, focused on KRAS.

Market information

SymbolPrimary exchanges


Voluntary delisting from AIM to go private
Lighthouse | 02 Apr 2024
Ready to ROCK as RXC008 enters the clinic
Update | 28 Feb 2024
Up to $870m KRAS deal marks third Jazz collaboration
Lighthouse | 07 Feb 2024

Recent News

AIM cancellation
01 May 2024
Proposed cancellation of admission to trading
02 Apr 2024
Redx to exhibit three posters at AACR
06 Mar 2024
First participant dosed in RXC008 Phase I trial
28 Feb 2024